CCL27b Inhibitors
Chemical inhibitors that can influence the activity of CCL27b operate by modulating various biological pathways and cellular processes which are interconnected with chemokine signaling. The inhibitors listed are not direct antagonists of CCL27b but rather influence the broader chemokine network, within which CCL27b functions. For instance, antagonists of chemokine receptors such as Maraviroc and AMD3100 target CCR5 and CXCR4, respectively. By blocking these receptors, they can alter the chemotactic landscape, potentially affecting CCL27b indirectly by modifying the chemokine milieu and possibly preventing CCL27b from exerting its full biological effect.
Moreover, this class includes inhibitors such as LY294002 and SB203580, which target intracellular signaling pathways like PI3K and p38 MAPK. These pathways are essential for the transmission of signals from chemokine receptors to the nucleus, resulting in cellular responses. By inhibiting these kinases, the compounds can disrupt the downstream effects of chemokine receptor engagement, which may in turn impact the regulatory network of chemokines, including CCL27b. The precise contribution of each inhibitor to the modulation of CCL27b activity is defined by its specificity and the role of the targeted molecule in chemokine signaling and immune cell function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 225002 | 182498-32-4 | sc-202803 sc-202803A | 1 mg 5 mg | $36.00 $102.00 | 2 | |
SB225002 is an inhibitor of the chemokine receptor CXCR2, demonstrating how inhibition of related receptors can modulate the chemokine network, which may include CCL27b. | ||||||
Reparixin | 266359-83-5 | sc-507446 | 5 mg | $78.00 | ||
Reparixin is an allosteric inhibitor of CXCR1/2, which could lead to alterations in chemokine signaling pathways, possibly influencing CCL27b's role within the chemokine network. | ||||||
Aprepitant | 170729-80-3 | sc-207299 | 1 mg | $173.00 | 4 | |
Aprepitant is a substance P antagonist, which blocks the neurokinin-1 receptor (NK1R). By impacting neuropeptide signaling, it may influence the chemokine regulatory environment, potentially affecting CCL27b activity. | ||||||
JTE 907 | 282089-49-0 | sc-203616 sc-203616A | 10 mg 50 mg | $289.00 $1122.00 | ||
JTE-907 is an inhibitor of the cannabinoid receptor CB2, which can impact immune cell migration and function, potentially affecting the network in which CCL27b operates. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can impact downstream signaling of chemokine receptors, potentially influencing the activity of CCL27b. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which can modulate inflammatory responses and, as a consequence, may influence the regulatory environment of chemokines including CCL27b. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor, which can affect the MAPK/ERK pathway, potentially altering the signaling environment of chemokine receptors and impacting CCL27b activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, which could affect chemokine receptor signaling, potentially influencing CCL27b signaling. | ||||||